PubRank

Australian Ovarian Cancer Study Group

Author PubWeight™ 161.84‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Large-scale genotyping identifies 41 new loci associated with breast cancer risk. Nat Genet 2013 8.24
2 Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clin Cancer Res 2008 8.17
3 Newly discovered breast cancer susceptibility loci on 3p24 and 17q23.2. Nat Genet 2009 7.30
4 Common variants at 19p13 are associated with susceptibility to ovarian cancer. Nat Genet 2010 4.51
5 A genome-wide association study identifies a new ovarian cancer susceptibility locus on 9p22.2. Nat Genet 2009 4.38
6 A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24. Nat Genet 2010 3.86
7 GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer. Nat Genet 2013 3.42
8 Genome-wide association analysis identifies three new breast cancer susceptibility loci. Nat Genet 2012 3.20
9 Whole-genome characterization of chemoresistant ovarian cancer. Nature 2015 3.06
10 Subtype-specific mutation of PPP2R1A in endometrial and ovarian carcinomas. J Pathol 2011 2.64
11 Talcum powder, chronic pelvic inflammation and NSAIDs in relation to risk of epithelial ovarian cancer. Int J Cancer 2008 2.14
12 Differentiating stage 1 epithelial ovarian cancer from benign ovarian tumours using a combination of tumour markers HE4, CA125, and CEA and patient's age. Gynecol Oncol 2013 2.11
13 Tagging single nucleotide polymorphisms in cell cycle control genes and susceptibility to invasive epithelial ovarian cancer. Cancer Res 2007 1.92
14 IL6-STAT3-HIF signaling and therapeutic response to the angiogenesis inhibitor sunitinib in ovarian clear cell cancer. Clin Cancer Res 2011 1.79
15 Epigenetic analysis leads to identification of HNF1B as a subtype-specific susceptibility gene for ovarian cancer. Nat Commun 2013 1.73
16 High resolution melting for mutation scanning of TP53 exons 5-8. BMC Cancer 2007 1.65
17 ABCB1 (MDR1) polymorphisms and ovarian cancer progression and survival: a comprehensive analysis from the Ovarian Cancer Association Consortium and The Cancer Genome Atlas. Gynecol Oncol 2013 1.61
18 Single nucleotide polymorphisms in the TP53 region and susceptibility to invasive epithelial ovarian cancer. Cancer Res 2009 1.59
19 Deregulation of MYCN, LIN28B and LET7 in a molecular subtype of aggressive high-grade serous ovarian cancers. PLoS One 2011 1.57
20 Aspirin, nonaspirin nonsteroidal anti-inflammatory drugs, acetaminophen and ovarian cancer survival. Cancer Epidemiol 2015 1.56
21 A dynamic inflammatory cytokine network in the human ovarian cancer microenvironment. Cancer Res 2011 1.55
22 Nonequivalent gene expression and copy number alterations in high-grade serous ovarian cancers with BRCA1 and BRCA2 mutations. Clin Cancer Res 2013 1.54
23 Amplicon-dependent CCNE1 expression is critical for clonogenic survival after cisplatin treatment and is correlated with 20q11 gain in ovarian cancer. PLoS One 2010 1.54
24 Validating genetic risk associations for ovarian cancer through the international Ovarian Cancer Association Consortium. Br J Cancer 2009 1.54
25 Mutational landscape of mucinous ovarian carcinoma and its neoplastic precursors. Genome Med 2015 1.50
26 Identification of six new susceptibility loci for invasive epithelial ovarian cancer. Nat Genet 2015 1.47
27 Platinum sensitivity-related germline polymorphism discovered via a cell-based approach and analysis of its association with outcome in ovarian cancer patients. Clin Cancer Res 2011 1.47
28 Obesity and risk of ovarian cancer subtypes: evidence from the Ovarian Cancer Association Consortium. Endocr Relat Cancer 2013 1.47
29 Evaluation of candidate stromal epithelial cross-talk genes identifies association between risk of serous ovarian cancer and TERT, a cancer susceptibility "hot-spot". PLoS Genet 2010 1.47
30 Association between invasive ovarian cancer susceptibility and 11 best candidate SNPs from breast cancer genome-wide association study. Hum Mol Genet 2009 1.42
31 SIK2 is a centrosome kinase required for bipolar mitotic spindle formation that provides a potential target for therapy in ovarian cancer. Cancer Cell 2010 1.42
32 Fine-scale mapping of the FGFR2 breast cancer risk locus: putative functional variants differentially bind FOXA1 and E2F1. Am J Hum Genet 2013 1.39
33 Recreational physical activity and epithelial ovarian cancer: a case-control study, systematic review, and meta-analysis. Cancer Epidemiol Biomarkers Prev 2007 1.36
34 Profiles of genomic instability in high-grade serous ovarian cancer predict treatment outcome. Clin Cancer Res 2012 1.35
35 Association between single-nucleotide polymorphisms in hormone metabolism and DNA repair genes and epithelial ovarian cancer: results from two Australian studies and an additional validation set. Cancer Epidemiol Biomarkers Prev 2007 1.34
36 Five polymorphisms and breast cancer risk: results from the Breast Cancer Association Consortium. Cancer Epidemiol Biomarkers Prev 2009 1.29
37 11q13 is a susceptibility locus for hormone receptor positive breast cancer. Hum Mutat 2012 1.26
38 Synthetic lethality between CCNE1 amplification and loss of BRCA1. Proc Natl Acad Sci U S A 2013 1.22
39 Common non-synonymous SNPs associated with breast cancer susceptibility: findings from the Breast Cancer Association Consortium. Hum Mol Genet 2014 1.22
40 RNF43 is a tumour suppressor gene mutated in mucinous tumours of the ovary. J Pathol 2013 1.20
41 Functional polymorphisms in the TERT promoter are associated with risk of serous epithelial ovarian and breast cancers. PLoS One 2011 1.20
42 Loss of lifestyle: health behaviour and weight changes after becoming a caregiver of a family member diagnosed with ovarian cancer. Support Care Cancer 2010 1.18
43 Genital powder use and risk of ovarian cancer: a pooled analysis of 8,525 cases and 9,859 controls. Cancer Prev Res (Phila) 2013 1.17
44 Tubal ligation and risk of ovarian cancer subtypes: a pooled analysis of case-control studies. Int J Epidemiol 2013 1.10
45 Endometrioid and clear cell ovarian cancers: a comparative analysis of risk factors. Eur J Cancer 2008 1.10
46 Identification and characterization of novel associations in the CASP8/ALS2CR12 region on chromosome 2 with breast cancer risk. Hum Mol Genet 2014 1.05
47 Cigarette smoking and risk of ovarian cancer: a pooled analysis of 21 case-control studies. Cancer Causes Control 2013 1.03
48 Combined and interactive effects of environmental and GWAS-identified risk factors in ovarian cancer. Cancer Epidemiol Biomarkers Prev 2013 1.02
49 Germline mutation in BRCA1 or BRCA2 and ten-year survival for women diagnosed with epithelial ovarian cancer. Clin Cancer Res 2014 1.01
50 Serous ovarian, fallopian tube and primary peritoneal cancers: a comparative epidemiological analysis. Int J Cancer 2008 1.01
51 A large-scale assessment of two-way SNP interactions in breast cancer susceptibility using 46,450 cases and 42,461 controls from the breast cancer association consortium. Hum Mol Genet 2013 1.00
52 Pre-invasive ovarian mucinous tumors are characterized by CDKN2A and RAS pathway aberrations. Clin Cancer Res 2012 0.99
53 Genome-wide association study of subtype-specific epithelial ovarian cancer risk alleles using pooled DNA. Hum Genet 2013 0.99
54 Comparison of expression profiles in ovarian epithelium in vivo and ovarian cancer identifies novel candidate genes involved in disease pathogenesis. PLoS One 2011 0.96
55 FGF receptor genes and breast cancer susceptibility: results from the Breast Cancer Association Consortium. Br J Cancer 2014 0.96
56 9q31.2-rs865686 as a susceptibility locus for estrogen receptor-positive breast cancer: evidence from the Breast Cancer Association Consortium. Cancer Epidemiol Biomarkers Prev 2012 0.95
57 PALB2, CHEK2 and ATM rare variants and cancer risk: data from COGS. J Med Genet 2016 0.95
58 Gynecological conditions and the risk of endometrial cancer. Gynecol Oncol 2011 0.95
59 The BARD1 Cys557Ser polymorphism and breast cancer risk: an Australian case-control and family analysis. Breast Cancer Res Treat 2008 0.95
60 Obesity and survival among women with ovarian cancer: results from the Ovarian Cancer Association Consortium. Br J Cancer 2015 0.95
61 Genetic variation in TYMS in the one-carbon transfer pathway is associated with ovarian carcinoma types in the Ovarian Cancer Association Consortium. Cancer Epidemiol Biomarkers Prev 2010 0.92
62 Prevalence and predictors of anxiety and depression in women with invasive ovarian cancer and their caregivers. Med J Aust 2010 0.92
63 No evidence for an association between the earwax-associated polymorphism in ABCC11 and breast cancer risk in Caucasian women. Breast Cancer Res Treat 2010 0.92
64 Risk factors for benign, borderline and invasive mucinous ovarian tumors: epidemiological evidence of a neoplastic continuum? Gynecol Oncol 2007 0.92
65 ABCA transporter gene expression and poor outcome in epithelial ovarian cancer. J Natl Cancer Inst 2014 0.91
66 Germline polymorphisms in an enhancer of PSIP1 are associated with progression-free survival in epithelial ovarian cancer. Oncotarget 2016 0.90
67 Estimating single nucleotide polymorphism associations using pedigree data: applications to breast cancer. Br J Cancer 2013 0.90
68 Polymorphism in the IL18 gene and epithelial ovarian cancer in non-Hispanic white women. Cancer Epidemiol Biomarkers Prev 2008 0.89
69 Pathways to the diagnosis of epithelial ovarian cancer in Australia. Med J Aust 2010 0.89
70 History of hypertension, heart disease, and diabetes and ovarian cancer patient survival: evidence from the ovarian cancer association consortium. Cancer Causes Control 2017 0.88
71 Common variants at the CHEK2 gene locus and risk of epithelial ovarian cancer. Carcinogenesis 2015 0.88
72 Fine-mapping identifies two additional breast cancer susceptibility loci at 9q31.2. Hum Mol Genet 2015 0.88
73 Physical symptoms, coping styles and quality of life in recurrent ovarian cancer: a prospective population-based study over the last year of life. Gynecol Oncol 2013 0.87
74 Changes in supportive care needs after first-line treatment for ovarian cancer: identifying care priorities and risk factors for future unmet needs. Psychooncology 2012 0.87
75 Xenobiotic-Metabolizing gene polymorphisms and ovarian cancer risk. Mol Carcinog 2010 0.86
76 Molecular profiling of low grade serous ovarian tumours identifies novel candidate driver genes. Oncotarget 2015 0.86
77 Genetic variation at CYP3A is associated with age at menarche and breast cancer risk: a case-control study. Breast Cancer Res 2014 0.86
78 Folate and related micronutrients, folate-metabolising genes and risk of ovarian cancer. Eur J Clin Nutr 2011 0.86
79 MicroRNA related polymorphisms and breast cancer risk. PLoS One 2014 0.85
80 Polymorphism in the GALNT1 gene and epithelial ovarian cancer in non-Hispanic white women: the Ovarian Cancer Association Consortium. Cancer Epidemiol Biomarkers Prev 2010 0.84
81 Genome-wide significant risk associations for mucinous ovarian carcinoma. Nat Genet 2015 0.83
82 Genetic variation in mitotic regulatory pathway genes is associated with breast tumor grade. Hum Mol Genet 2014 0.83
83 Estrogen receptor beta rs1271572 polymorphism and invasive ovarian carcinoma risk: pooled analysis within the Ovarian Cancer Association Consortium. PLoS One 2011 0.83
84 Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus. Nat Commun 2016 0.82
85 Cis-eQTL analysis and functional validation of candidate susceptibility genes for high-grade serous ovarian cancer. Nat Commun 2015 0.82
86 High levels of genomic aberrations in serous ovarian cancers are associated with better survival. PLoS One 2013 0.82
87 Prevalence and predictors of insomnia in women with invasive ovarian cancer: anxiety a major factor. Eur J Cancer 2009 0.82
88 MicroRNA genes and their target 3'-untranslated regions are infrequently somatically mutated in ovarian cancers. PLoS One 2012 0.82
89 The responses of research participants and their next of kin to receiving feedback of genetic test results following participation in the Australian Ovarian Cancer Study. Genet Med 2013 0.82
90 Evaluation of variation in the phosphoinositide-3-kinase catalytic subunit alpha oncogene and breast cancer risk. Br J Cancer 2011 0.81
91 Paclitaxel sensitivity in relation to ABCB1 expression, efflux and single nucleotide polymorphisms in ovarian cancer. Sci Rep 2014 0.81
92 Circulating 25-hydroxyvitamin D and survival in women with ovarian cancer. Am J Clin Nutr 2015 0.80
93 Evaluating the ovarian cancer gonadotropin hypothesis: a candidate gene study. Gynecol Oncol 2014 0.80
94 Incomplete pregnancy and risk of ovarian cancer: results from two Australian case-control studies and systematic review. Cancer Causes Control 2009 0.80
95 Network-Based Integration of GWAS and Gene Expression Identifies a HOX-Centric Network Associated with Serous Ovarian Cancer Risk. Cancer Epidemiol Biomarkers Prev 2015 0.80
96 Genome-wide Analysis Identifies Novel Loci Associated with Ovarian Cancer Outcomes: Findings from the Ovarian Cancer Association Consortium. Clin Cancer Res 2015 0.79
97 No evidence that protein truncating variants in BRIP1 are associated with breast cancer risk: implications for gene panel testing. J Med Genet 2016 0.79
98 Polymorphisms in the FGF2 gene and risk of serous ovarian cancer: results from the ovarian cancer association consortium. Twin Res Hum Genet 2009 0.79
99 Chronic Recreational Physical Inactivity and Epithelial Ovarian Cancer Risk: Evidence from the Ovarian Cancer Association Consortium. Cancer Epidemiol Biomarkers Prev 2016 0.78
100 Physical activity in women with ovarian cancer and its association with decreased distress and improved quality of life. Psychooncology 2010 0.78
101 Germ-line variation at a functional p53 binding site increases susceptibility to breast cancer development. Hugo J 2010 0.78
102 Beyond parity: association of ovarian cancer with length of gestation and offspring characteristics. Am J Epidemiol 2009 0.78
103 Polymorphisms in stromal genes and susceptibility to serous epithelial ovarian cancer: a report from the Ovarian Cancer Association Consortium. PLoS One 2011 0.78
104 Medical costs and outcomes for Australian women with ovarian cancer: a patient-level analysis over 2.5 years. Int J Gynecol Cancer 2010 0.78
105 Association between ambient ultraviolet radiation and risk of epithelial ovarian cancer. Cancer Prev Res (Phila) 2012 0.78
106 Pericytes Promote Malignant Ovarian Cancer Progression in Mice and Predict Poor Prognosis in Serous Ovarian Cancer Patients. Clin Cancer Res 2015 0.77
107 PPM1D Mosaic Truncating Variants in Ovarian Cancer Cases May Be Treatment-Related Somatic Mutations. J Natl Cancer Inst 2016 0.77
108 Copy number aberrations in benign serous ovarian tumors: a case for reclassification? Clin Cancer Res 2011 0.77
109 History of Comorbidities and Survival of Ovarian Cancer Patients, Results from the Ovarian Cancer Association Consortium. Cancer Epidemiol Biomarkers Prev 2017 0.77
110 Inherited variants in the inner centromere protein (INCENP) gene of the chromosomal passenger complex contribute to the susceptibility of ER-negative breast cancer. Carcinogenesis 2015 0.76
111 Connecting patients, researchers and clinical genetics services: the experiences of participants in the Australian Ovarian Cancer Study (AOCS). Eur J Hum Genet 2014 0.76
112 Dietary folate and related micronutrients, folate-metabolising genes, and ovarian cancer survival. Gynecol Oncol 2013 0.76
113 No evidence for PALB2 methylation in high-grade serous ovarian cancer. J Ovarian Res 2013 0.76
114 Investigation of Exomic Variants Associated with Overall Survival in Ovarian Cancer. Cancer Epidemiol Biomarkers Prev 2016 0.75
115 Re: Predictive value of symptoms for early detection of ovarian cancer. J Natl Cancer Inst 2010 0.75
116 Corrigendum: Whole-genome characterization of chemoresistant ovarian cancer. Nature 2015 0.75
117 Corrigendum: Common variants at 19p13 are associated with susceptibility to ovarian cancer. Nat Genet 2015 0.75
118 An intergenic risk locus containing an enhancer deletion in 2q35 modulates breast cancer risk by deregulating IGFBP5 expression. Hum Mol Genet 2016 0.75
119 Prostate cancer susceptibility polymorphism rs2660753 is not associated with invasive ovarian cancer. Cancer Epidemiol Biomarkers Prev 2011 0.75
120 Erratum to: Mutational landscape of mucinous ovarian carcinoma and its neoplastic precursors. Genome Med 2017 0.75
121 Use of common analgesic medications and ovarian cancer survival: results from a pooled analysis in the Ovarian Cancer Association Consortium. Br J Cancer 2017 0.75
122 Loss of heterozygosity: what is it good for? BMC Med Genomics 2015 0.75
123 Serous ovarian and primary peritoneal cancers: A comparative analysis of clinico-pathological features, molecular subtypes and treatment outcome. Gynecol Oncol 2016 0.75
124 Racial/ethnic differences in the epidemiology of ovarian cancer: a pooled analysis of 12 case-control studies. Int J Epidemiol 2017 0.75
125 EIF1AX and NRAS mutations co-occur and cooperate in low-grade serous ovarian carcinomas. Cancer Res 2017 0.75
126 A comparison of the FACT-G and the Supportive Care Needs Survey (SCNS) in women with ovarian cancer: unidimensionality of constructs. Qual Life Res 2011 0.75
127 Menstrual pain and risk of epithelial ovarian cancer: results from the Ovarian Cancer Association Consortium. Int J Cancer 2017 0.75